FDA’s 2025 diversity action plans demand inclusive patient cohorts, yet biotech clinical operations leaders miss 30% of targeted patients (e.g., rare disease groups) due to manual pre-screening and consent processes, delaying trials by 3–6 months. In 2025, streamlined recruitment is critical for regulatory and funding success. Cloudbyz’s Salesforce-native Patient Recruitment portal standardizes enrollment, boosting accessibility and compliance. This article details how Cloudbyz empowers biotechnology operations leaders to meet enrollment goals, positioning it as the leader in patient-centric trials.
Biotech trials for rare diseases or oncology require precise cohorts (e.g., genetic mutations). Manual pre-screening—site staff using paper forms or siloed tools—misses 30% of eligible patients due to inconsistent eligibility checks, per Cloudbyz’s blog on recruitment challenges. Paper-based consent deters 20% of diverse patients due to language or logistical barriers. Manual budget tracking misaligns site payments, causing 20% overruns. For a Phase II trial, delays cost $500K monthly, risking funding rounds.
Cloudbyz’s Patient Recruitment portal delivers:
Automated Pre-Screening: Standardizes eligibility checks, boosting enrollment by 25%, as shown in a Middle Eastern CRO case study.
Digital eConsent: Multilingual, mobile-friendly forms increase diverse participation by 20%.
Budget Tracking: CTBM monitors site payments in real-time, reducing overruns by 15%.
Patient Engagement Tools: Provide study updates, improving retention by 10%.
A Middle Eastern CRO used Cloudbyz to enroll 35% more rare disease patients for a biotech trial, meeting FDA diversity goals 2 months early. Unlike Veeva’s traditional tools, Cloudbyz’s DCT-ready portal supports biotech’s lean operations.
With 50% of trials decentralized by 2026 (IQVIA, 2025), inclusive recruitment is non-negotiable. Cloudbyz’s chatter-based collaboration enables community partnerships, addressing trust barriers. Its 25% carbon footprint reduction aligns with biotech’s ESG goals, per Cloudbyz’s sustainability claims.
Cloudbyz’s portal integrates with CTMS and EDC, offering a unified solution that reduces recruitment costs by 10–15% compared to fragmented tools. Its scalability supports biotech’s growth from Phase I to III.
Biotech operations leaders can achieve inclusive enrollment with Cloudbyz. Visit cloudbyz.com to download our whitepaper on patient-centric trials or schedule a demo.